Drug
Arct 2303
Arct 2303: highest development phase Phase 3, developed by Arcturus Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Arcturus Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARCT-2303 NCT06279871 | Phase 3 | COVID-19 |
Latest
No recent events.
Follow Arct 2303 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.